Vol. 16 No. 4 Supplement, 2013

Table of Contents


Emerging Novel Therapies in Recurrent Ovarian Cancer: Anti-angiogenesis

Full Article

E Pujade-Lauraine

Hong Kong J Radiol 2013;16(Suppl):S4-8

Ovarian cancer is the leading cause of gynaecological cancer death in Hong Kong. It is often diagnosed late due to the absence of a means for routine screening. Up to 75% of patients

From Complexity to Simplicity: Best Level of Evidence for Metastatic Colorectal Cancer

Full Article

KO Lam

Hong Kong J Radiol 2013;16(Suppl):S9-16

Simplicity is enormously complex in the treatment of metastatic colorectal cancer. In terms of survival, life expectancy of patients with metastatic colorectal cancer improved substantially from 3 to 6 months

Optimising Systemic Therapy in Metastatic Colorectal Cancer

Full Article

EP Hui

Hong Kong J Radiol 2013;16(Suppl):S17-22

The last 30 years have witnessed numerous advances in the management of metastatic colorectal cancer leading to an expansion in treatment options and improvement in treatment outcomes. The management of

Achieving Response and Improving Outcomes of First-line Therapy for Advanced Non–small-cell Lung Cancer

Full Article

KK Loh

Hong Kong J Radiol 2013;16(Suppl):S23-8

The first-line treatment paradigm for advanced non–small-cell lung cancer (NSCLC) has evolved in the past few decades, with marked improvements in therapeutic strategies and choice of active agents. Prior

Importance of BRAF Testing in Unresectable or Metastatic Melanoma

Full Article


Hong Kong J Radiol 2013;16(Suppl):S29-33

BRAF is a protein kinase in the mitogen-activated protein kinase pathway that regulates cell proliferation, differentiation, and survival. Mutation in the BRAF gene can lead to aberrant activation of the

Advances in Treatment for Patients with Unresectable or Metastatic BRAF V600 Mutated Melanoma

Full Article

ACH Ying

Hong Kong J Radiol 2013;16(Suppl):S34-8

Melanoma is widely prevalent among western populations and is a relatively rare malignancy in the local Chinese population. In local Chinese patients, clinicians should be wary of suspicious pigmented lesions

Post-prostatectomy Radiotherapy

Full Article


Hong Kong J Radiol 2013;16(Suppl):S39-43

Patients with localised prostate cancer can be cured with radical prostatectomy alone. Nevertheless, many of them may develop local failure due to positive surgical margins or residual disease from extraprostatic

Recent Advances in the Treatment for Metastatic Castration-Refractory Prostate Cancer

Full Article

PWK Kwong

Hong Kong J Radiol 2013;16(Suppl):S44-9

In Hong Kong, prostate cancer is the third most common cancer in men, with increasing incidence over the past two decades. Advanced prostate cancer is typically sensitive to androgen-deprivation therapy,

What Physicians Need to Know About Biosimilars

Full Article

BMY Cheung

Hong Kong J Radiol 2013;16(Suppl):S50-4

Biologics are complex proteins derived from living organisms that have been used successfully in treating many different diseases. As some biologics approach patent expiration, the development of drugs that are


Anti-angiogenesis Therapy in Lung Cancer: a Practical Approach

Full Article


Hong Kong J Radiol 2013;16(Suppl):S55-9

In advanced pulmonary carcinoma, determination of epidermal growth factor receptor (EGFR) mutation status, histology, and anaplastic lymphoma kinase (ALK) mutation status can be highly instructive for guiding the course of

Post-transplant Lymphoproliferative Diseases: a Case Report and Discussion of Management

Full Article

T Chan

Hong Kong J Radiol 2013;16(Suppl):S60-4

Post-transplant lymphoproliferative disorders (PTLD) are lymphoid or plasmacytic proliferations that develop in immunosuppressed individuals, particularly in recipients of solid organs, bone marrow, or stem cell allograft. Although rare in the

Prostate Cancer: Diagnosis, Imaging, and Robotic Surgery

Full Article


Hong Kong J Radiol 2013;16(Suppl):S66-8

Prostate cancer is the third most common cancer affecting men in Hong Kong, and the fifth leading cause of cancer death in Hong Kong males. The diagnosis of prostate cancer